- Major tech companies like Microsoft, Google, Amazon, and OpenAI are heavily investing in and competing within the AI revolution.
- Trump-era tariffs may benefit AI stocks, while Google faces DOJ rulings and secures a default search engine deal with Apple.
- AI stocks are benefiting from the trend of onshoring and tariffs implemented during the Trump era.
- Trump-era tariffs are benefiting AI stocks, and the FDA expanded the patient base for WAKIX.
Harmony Biosciences Holdings, Inc. presented company data at a congress held in Lisbon, Portugal, on August 26, 2025.
1 report, 1 independent
Updated Aug 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Harmony Biosciences Holdings, Inc. presented company data at a congress held in Lisbon, Portugal, on August 26, 2025.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Trump-era tariffs are benefiting AI stocks, and the FDA expanded the patient base for WAKIX.Also in this story
- BP-205 pipeline offers future growth potential, and WAKIX revenue drives company financial performance.
- Trump-era tariffs benefit certain AI stocks, and Aptevo Therapeutics regained compliance with Nasdaq listing rules.
- MaxCyte licensed its platform technology to Adicet Bio, Inc. for cell therapies, amid reports that Trump-era tariffs benefit AI stocks.
The entities involved
-
Portugal
country in Southwestern Europe
Coverage
Newest first; wire copies grouped- Business WireHarmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress PLYMOUTH MEETING, Pa., August 26, 2025--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY